Companies: Hifas da Terra, AMSbiopharma, CIFGA and Tecnologías Plexus.
Objective: The overall objective of this project is the implementation of an accelerated development through prediction based on the integration of chemical and biological data for the discovery of new anti-COVID-19 treatments from fungal and microalgae extracts. The consortium that will carry out this project is formed by 3 SMEs and 1 large Galician company: Hyphae da Terra (leader of the project), AMSbiopharma, CIFGA and Plexus, with the support of the University of Santiago de Compostela as a subcontracted collaborating entity, which will collaborate jointly for its execution. Thus, DIGITAL-BIOCoV will make use of the incorporation of digital technologies in research and development during the discovery phase of bioactive fractions or molecules against SARS-CoV-2 from the integration of bioactivity and chemical data that allow exploring their patentability, value or originality for the pharmaceutical market.
Total budget: 314.486,93 €. This project is subsidized by the Galician Agency for Innovation (GAIN), financed by ERDF funds and supported by the Xunta de Galicia through the second vice-presidency and Consellería de Economía, Empresa e Innovación. The operation is funded through the CONECTA COVID 2021 program under the REACT-EU axis of the Feder Galicia 2014-2020 operational program, as part of the European Union’s response to the COVID-19 pandemic.